CGCN GROUP, LLC

Lobbying for VERTEX PHARMACEUTICALS INCORPORATED · Biopharmaceutical Company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $80,000.00 income · posted Oct 20, 2025

Bills named in this filing 2

Lobbying activity 2

Health Issues

Access to innovative non-opioid medicines.

Medicare/Medicaid

Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.